Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05335148
Other study ID # 032112
Secondary ID Pro2022000357
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 10, 2022
Est. completion date June 1, 2024

Study information

Verified date November 2023
Source Rutgers, The State University of New Jersey
Contact Bruce Haffty, MD
Phone 732-235-5203
Email hafftybg@cinj.rutgers.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently, there are no approved medications for the prevention and treatment of radiation-induced dermatitis, or skin discoloration/burning due to radiation therapy, because there is little evidence to guide treatment. The purpose of the research is to better understand the factors associated with radiation-induced dermatitis and to explore the efficacy of low-dose colchicine in reducing the proportion of patients with radiation-induced dermatitis who undergo radiation treatment for head and neck cancer. If you take part in the research, you will be asked to take 0.6 mg once a day by mouth. The participants time in the study will take less than a minute a day to take the pill and 20 minutes to complete survey questions during follow-up visits.


Description:

A phase I study for evaluating the safety of oral colchicine in preventing and treating radiation-induced dermatitis among head and neck cancer patients who will receive RT for HNC. Prior to receiving RT, each subject will be receiving either the standard of care or low-dose oral colchicine (No randomization). There will be a comparison of the proportion of radiation-induced dermatitis in the two study arms. The individuals in the standard of care arm will receive a placebo colchicine pill once a day. Those who are in the experimental arm will receive 0.6 mg of oral colchicine once a day. The primary endpoint is the safety and tolerability of oral colchicine. The proportions of grade 2-4 radiation-induced dermatitis at the end of Radiation therapy (RT) and at the first follow-up three-four weeks post-treatment in these two study arms are the secondary study endpoints. In addition, pain, erythema, and health-related quality-of-life will be evaluated. The study subjects will receive radiation therapy (RT) as scheduled and will meet with their clinicians for their follow-up visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Eight years or older with HNC diagnosis confirmed histologically o Stage 1-3 HNC pathologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, larynx, hypopharynx, nasopharyngeal, or oral cavity - Plan to receive radiotherapy (>60 Gy), chemo-irradiation or bio-radiation either as primary or as a post-operative treatment to the head and neck region - Eastern Cooperative Oncology Group Performance Status (ECOGPS) performance status 0 or 1 - Comply with the study protocol - Capable of signing a written informed consent Exclusion Criteria: - An allergy, intolerance, or contraindication to colchicine - Current treatment with colchicine for medical conditions, e.g. gout and Familial Mediterranean Fever (FMF) - Estimated glomerular filtration rate (GFR) < 55 ml/min since colchicine should not be given - Severe liver disease or current aminotransferase levels of more than 1.5 times the upper limit of the normal range - Previous irradiation to the head and/or neck region - Distant metastatic disease or locally recurrent disease - Pre-existing skin rashes, ulcerations, or open wounds in the treatment area - Known allergic and other systemic skin diseases even when not directly affecting irradiated fields - Substance abuse, medical conditions, and/or social issues that would limit conduct or follow-up in the research study, in the opinion of the investigator - Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator - Using high doses of non-steroidal anti-inflammatory drugs - Pregnant and lactating women - Psychiatric illness that would prevent the patient from giving informed consent - Taking cetuximab or other radiosensitizing agents.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
oral colchicine(0.6 mg) once a day
The standard of care arm will receive a placebo colchicine pill once a day

Locations

Country Name City State
United States RWJBarnabas Health - Cooperman Barnabas Livingston New Jersey
United States Robert Wood Johnson University Hospital New Brunswick New Jersey
United States Rutgers, The State University of New Jersey Board Contact: New Brunswick New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Rutgers, The State University of New Jersey

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Health-Related Quality-of-Life - Questionnaire Health-related quality of life (HRQOL) measured before, during, and after Radiation therapy, with a validated HRQOL questionnaire, European Organization for Research and Treatment of Cancer (EORTC) 10 weeks
Other Health-Related Quality-of-Life - Quality of Life Questionnaire Treatment of Cancer European Organization for Research and Treatment of Cancer (EORTC). A validated questionnaire developed to assess the quality of life of cancer patients.
Quality of Life Questionnaire Core Module (QLQ-C30) version- 3.
10 weeks
Primary Pain - Visual Analogue Scale (VAS) Pain (within radiation fields): assessed before radiotherapy, weekly during radiotherapy, and at the end of treatment with the visual analogue scale (VAS) (from 0 = no pain to 100 = maximum pain) 10 weeks
Secondary Erythema - Common Toxicity Criteria for Adverse Events (CTCAE) The National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) scale defines acute skin reactions to radiation occurring within the 90 days after therapy.
Grade 1: faint erythema or dry desquamation. Arising within the first two to four weeks of treatment, these reactions cause skin redness, warmth, and a rash-like appearance. The patient may complain that their skin feels tight or sensitive.
Grade 2: moderate to brisk erythema; patchy, moist desquamation usually confined to skin folds or creases. Moderate edema, dryness, pruritus, and flaking of skin layers (dry desquamation) also may occur.
Grade 3: moist desquamation in areas other than creases and skinfolds. Bleeding may arise from minor trauma, such as abrasion.
Grade 4: life-threatening consequences, such as full-thickness skin ulcers, necrosis, and spontaneous bleeding.
Grade 5: death.
10 weeks
See also
  Status Clinical Trial Phase
Completed NCT04324645 - Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies
Completed NCT04776083 - Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients Phase 3
Completed NCT01635270 - Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma Phase 2
Terminated NCT03724422 - HO Prophylaxis Therapy for Distal Humerus Fractures N/A
Recruiting NCT03731130 - Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Recruiting NCT04983095 - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase 3
Recruiting NCT05721053 - Improving Outcomes for Older Adults Undergoing Radiation Therapy
Active, not recruiting NCT04764227 - Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) Phase 2
Not yet recruiting NCT05821452 - Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma Phase 2
Recruiting NCT04362306 - Radiation Oncology Patient Medical Physics Intervention Study N/A
Completed NCT01917890 - Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer N/A
Not yet recruiting NCT05648253 - Hyivy Device in Post-radiation Patients N/A
Completed NCT03235427 - The CAROLE (CArdiac Related Oncologic Late Effects) Study
Recruiting NCT03142425 - Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy
Recruiting NCT05406063 - Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases N/A
Recruiting NCT03071289 - A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer Phase 3
Recruiting NCT03213925 - Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer Phase 2
Recruiting NCT06128863 - Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial Phase 2
Recruiting NCT05351294 - Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet Phase 3
Recruiting NCT05817201 - Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Phase 2/Phase 3